NTRA Natera, Inc. Common Stock Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
08:30
Jul 19
Choi Chang-gyu Director, NH Investment & Securities 815 Money Talk (815머니톡)
Buy Guardant Health and Natera on biotech rotation.
Retail investors are rotating out of crowded tech positions into biotech and healthcare. Guardant Health (liquid biopsy, early cancer detection) and Natera (genetic testing, recurrence monitoring) are leading liquid-biopsy companies that rank high among retail purchases. This rotation into defensive biotech leaders gives them added demand and supports a positive outlook.
NTRA 1ST
MED
04:27
Jun 12
FirstSquawk Newswire (@FirstSquawk)
RBC restarted coverage on Natera Inc with an Outperform rating and a price target of 275 dollars.
NTRA
15:45
May 16
Ozark Bull market enjoyer, crypto trader
Reports David Tepper (Druck) Q1 2026 13F additions; speaker provides no personal thesis.
NTRA
HIGH

About NTRA Analyst Coverage

Buzzberg tracks NTRA (Natera, Inc. Common Stock) across 3 sources. 1 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (33%). 3 total trade ideas tracked. Past 7 days: 1 bullish. Latest voices: Choi Chang-gyu, FirstSquawk, Ozark.